Product: Flt3/CD135 Mouse Monoclonal Antibody
Catalog: BF8259
Description: Mouse monoclonal antibody to Flt3/CD135
Application: WB IHC IF/ICC
Reactivity: Human
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 112 kDa; 113kD(Calculated).
Uniprot: P36888

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Mouse
Application:
WB 1:500-1:3000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human
Clonality:
Monoclonal [AFfirm8259]
Specificity:
Flt3/CD135 Mouse Monoclonal Antibody detects endogenous levels of total Flt3/CD135
Conjugate:
Unconjugated.
Purification:
Affinity-chromatography.
Storage:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CD 135; CD135; CD135 antigen; Fetal liver kinase 2; FL cytokine receptor; Flk 2; Flk2; Flt 3; FLT-3; Flt3; FLT3_HUMAN; FMS like tyrosine kinase 3; Fms related tyrosine kinase 3; Fms-like tyrosine kinase 3; Growth factor receptor tyrosine kinase type III; Ly-72; OTTHUMP0000004234; Receptor type tyrosine protein kinase FLT3; Stem cell tyrosine kinase 1; Stk 1; STK-1; Stk1; Tyrosine protein kinase receptor FLT3; Tyrosine-protein kinase receptor FLT3;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P36888 FLT3_HUMAN:

Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia.

Sequence:
MPALARDGGQLPLLVVFSAMIFGTITNQDLPVIKCVLINHKNNDSSVGKSSSYPMVSESPEDLGCALRPQSSGTVYEAAAVEVDVSASITLQVLVDAPGNISCLWVFKHSSLNCQPHFDLQNRGVVSMVILKMTETQAGEYLLFIQSEATNYTILFTVSIRNTLLYTLRRPYFRKMENQDALVCISESVPEPIVEWVLCDSQGESCKEESPAVVKKEEKVLHELFGTDIRCCARNELGRECTRLFTIDLNQTPQTTLPQLFLKVGEPLWIRCKAVHVNHGFGLTWELENKALEEGNYFEMSTYSTNRTMIRILFAFVSSVARNDTGYYTCSSSKHPSQSALVTIVEKGFINATNSSEDYEIDQYEEFCFSVRFKAYPQIRCTWTFSRKSFPCEQKGLDNGYSISKFCNHKHQPGEYIFHAENDDAQFTKMFTLNIRRKPQVLAEASASQASCFSDGYPLPSWTWKKCSDKSPNCTEEITEGVWNRKANRKVFGQWVSSSTLNMSEAIKGFLVKCCAYNSLGTSCETILLNSPGPFPFIQDNISFYATIGVCLLFIVVLTLLICHKYKKQFRYESQLQMVQVTGSSDNEYFYVDFREYEYDLKWEFPRENLEFGKVLGSGAFGKVMNATAYGISKTGVSIQVAVKMLKEKADSSEREALMSELKMMTQLGSHENIVNLLGACTLSGPIYLIFEYCCYGDLLNYLRSKREKFHRTWTEIFKEHNFSFYPTFQSHPNSSMPGSREVQIHPDSDQISGLHGNSFHSEDEIEYENQKRLEEEEDLNVLTFEDLLCFAYQVAKGMEFLEFKSCVHRDLAARNVLVTHGKVVKICDFGLARDIMSDSNYVVRGNARLPVKWMAPESLFEGIYTIKSDVWSYGILLWEIFSLGVNPYPGIPVDANFYKLIQNGFKMDQPFYATEEIYIIMQSCWAFDSRKRPSFPNLTSFLGCQLADAEEAMYQNVDGRVSECPHTYQNRRPFSREMDLGLLSPQAQVEDS

PTMs - P36888 As Substrate

Site PTM Type Enzyme
N43 N-Glycosylation
N100 N-Glycosylation
N151 N-Glycosylation
Y166 Phosphorylation
N306 N-Glycosylation
N323 N-Glycosylation
T343 Phosphorylation
N351 N-Glycosylation
N354 N-Glycosylation
Y416 Phosphorylation
Y572 Phosphorylation P36888 (FLT3)
S574 Phosphorylation
Y589 Phosphorylation P36888 (FLT3)
Y591 Phosphorylation P36888 (FLT3) , P11309 (PIM1)
Y597 Phosphorylation P36888 (FLT3)
Y599 Phosphorylation P36888 (FLT3)
K602 Ubiquitination
K614 Ubiquitination
K623 Ubiquitination
Y630 Phosphorylation
K634 Ubiquitination
K644 Ubiquitination
K719 Ubiquitination
Y726 Phosphorylation P36888 (FLT3)
T728 Phosphorylation
S759 Phosphorylation
Y768 Phosphorylation P36888 (FLT3)
K772 Ubiquitination
Y793 Phosphorylation P36888 (FLT3)
S840 Phosphorylation
Y842 Phosphorylation P36888 (FLT3)
Y919 Phosphorylation
K932 Ubiquitination
S935 Phosphorylation
Y955 Phosphorylation P36888 (FLT3)
T968 Phosphorylation
Y969 Phosphorylation P36888 (FLT3)
S993 Phosphorylation

PTMs - P36888 As Enzyme

Substrate Site Source
P29353-7 (SHC1) Y239 Uniprot
P29353-7 (SHC1) Y240 Uniprot
P29353-7 (SHC1) Y318 Uniprot
P29353 (SHC1) Y349 Uniprot
P29353 (SHC1) Y350 Uniprot
P29353 (SHC1) Y427 Uniprot
P35222 (CTNNB1) Y654 Uniprot
P36888 (FLT3) Y572 Uniprot
P36888 (FLT3) Y589 Uniprot
P36888 (FLT3) Y591 Uniprot
P36888 (FLT3) Y597 Uniprot
P36888-1 (FLT3) Y599 Uniprot
P36888 (FLT3) Y726 Uniprot
P36888 (FLT3) Y768 Uniprot
P36888 (FLT3) Y793 Uniprot
P36888 (FLT3) Y842 Uniprot
P36888 (FLT3) Y955 Uniprot
P36888 (FLT3) Y969 Uniprot
Q15118 (PDK1) Y243 Uniprot

Research Backgrounds

Function:

Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.

PTMs:

N-glycosylated, contains complex N-glycans with sialic acid.

Autophosphorylated on several tyrosine residues in response to FLT3LG binding. FLT3LG binding also increases phosphorylation of mutant kinases that are constitutively activated. Dephosphorylated by PTPRJ/DEP-1, PTPN1, PTPN6/SHP-1, and to a lesser degree by PTPN12. Dephosphorylation is important for export from the endoplasmic reticulum and location at the cell membrane.

Rapidly ubiquitinated by UBE2L6 and the E3 ubiquitin-protein ligase SIAH1 after autophosphorylation, leading to its proteasomal degradation.

Subcellular Location:

Membrane>Single-pass type I membrane protein. Endoplasmic reticulum lumen.
Note: Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen. The activated kinase is rapidly targeted for degradation.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia.

Subunit Structure:

Monomer in the absence of bound FLT3LG. Homodimer in the presence of bound FLT3LG. Interacts with FIZ1 following ligand activation (By similarity). Interacts with FES, FER, LYN, FGR, HCK, SRC and GRB2. Interacts with PTPRJ/DEP-1 and PTPN11/SHP2. Interacts with RNF115 and RNF126 (By similarity).

(Microbial infection) Interacts with human cytomegalovirus protein UL7.

Family&Domains:

The juxtamembrane autoregulatory region is important for normal regulation of the kinase activity and for maintaining the kinase in an inactive state in the absence of bound ligand. Upon tyrosine phosphorylation, it mediates interaction with the SH2 domains of numerous signaling partners. In-frame internal tandem duplications (ITDs) result in constitutive activation of the kinase. The activity of the mutant kinase can be stimulated further by FLT3LG binding.

Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.

Research Fields

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer.   (View pathway)

· Organismal Systems > Immune system > Hematopoietic cell lineage.   (View pathway)

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.